参考文献/References:
[1] Damluji AA,van Diepen S,Katz JN,et al. Mechanical complications of acute myocardial infarction:a scientific statement from the American Heart Association[J]. Circulation,2021,144(2):e16-e35.
[2] Gulati R,Behfar A,Narula J,et al. Acute myocardial infarction in young individuals[J]. Mayo Clin Proc,2020,95(1):136-156.
[3] Wang H,Liu Z,Shao J,et al. Immune and inflammation in acute coronary syndrome:molecular mechanisms and therapeutic implications[J]. J Immunol Res,2020,2020:4904217.
[4] Han F,Yan B. Three novel ATG16L1 mutations in a patient with acute myocardial infarction and coronary artery ectasia:a case report [J]. Medicine(Baltimore),2021,100(4):e24497.
[5] Reed GW,Rossi JE,Cannon CP. Acute myocardial infarction[J]. Lancet,2017,389(10065):197-210.
[6] Jang SJ,Yeo I,Feldman DN,et al. Associations between hospital length of stay,30-day readmission,and costs in ST-segment-elevation myocardial infarction after primary percutaneous coronary intervention:a nationwide readmissions database analysis[J]. J Am Heart Assoc,2020,9(11):e015503.
[7] Liu Y,Zhang L,Yang Y. Tirofiban hydrochloride sodium chloride injection combined with cardiovascular intervention in the treatment of acute myocardial infarction[J]. Pak J Med Sci,2020,36(2):54-58.
[8] Amin M,Kella D,Killu AM,et al. Sudden cardiac arrest and ventricular arrhythmias following first type Ⅰ?myocardial infarction in the contemporary era[J]. J Cardiovasc Electrophysiol,2019,30(12):2869-2876.
[9] Xu H,Yang Y,Wang C,et al. Association of hospital-level differences in care with outcomes among patients with acute ST-segment elevation myocardial infarction in China[J]. JAMA Netw Open,2020,3(10):e2021677.
[10] Sears CG,Poulsen AH,Eliot M,et al. Urine cadmium and acute myocardial infarction among never smokers in the Danish Diet,Cancer and Health cohort[J]. Environ Int,2021,150:106428.
[11] Basuoni A,El-Naggar W,Mahdy M,et al. Effect of intracoronary tirofiban following aspiration thrombectomy on infarct size,in patients with large anterior ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Coron Artery Dis,2020,31(3):255-259.
[12] Tanswell P,Modi N,Combs D,et al. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction[J]. Clin Pharmacokinet,2002,41(15):1229-1245.
[13] Tsivgoulis G,Kargiotis O,de Marchis G,et al. Off-label use of intravenous thrombolysis for acute ischemic stroke:a critical appraisal of randomized and real-world evidence[J]. Ther Adv Neurol Disord,2021,14:1756286421997368.
[14] Thiebaut AM,Gauberti M,Ali C,et al. The role of plasminogen activators in stroke treatment:fibrinolysis and beyond[J]. Lancet Neurol,2018,17(12):1121-1132.
[15] Morales-Ponce FJ,Lozano-Cid FJ,Martinez-Romero P,et al. Intracoronary tenecteplase versus abciximab as adjunctive treatment during primary percutaneous coronary intervention in patients with anterior myocardial infarction[J]. EuroIntervention,2019,14(16):1668-1675.
[16] Li Y,Cui R,Fan F,et al. The efficacy and safety of ischemic stroke therapies:an umbrella review[J]. Front Pharmacol,2022,13:924747.
[17] Benedict CR,Refino CJ,Keyt BA,et al. New variant of human tissue plasminogen activator(TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA[J]. Circulation,1995,92(10):3032-3040.
[18] Thomas GR,Thibodeaux H,Errett CJ,et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding[J]. Stroke,1994,25(10):2072-2078,discussion 2078-2079.
[19] Keyt BA,Paoni NF,Refino CJ,et al. A faster-acting and more potent form of tissue plasminogen activator [J]. Proc Natl Acad Sci U S A,1994,91(9):3670-3674.
[20] Collen D,Stassen JM,Yasuda T,et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant,in a combined arterial and venous thrombosis model in the dog[J]. Thromb Haemost,1994,72(1):98-104.
[21] van de Werf F,Cannon CP,Luyten A,et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction:the ASSENT-1 trial. The ASSENT-1 Investigators[J]. Am Heart J,1999,137(5):786-791.
[22] van de Werf F,Adgey J,Ardissino D,et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction:the ASSENT-2 double-blind randomised trial[J]. Lancet,1999,354(9180):716-722.
[23] Assessment of the safety and efficacy of a new thrombolytic regimen(ASSENT)-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin,abciximab,or unfractionated heparin:the ASSENT-3 randomised trial in acute myocardial infarction [J]. Lancet,2001,358(9282):605-613.
[24] Wang HB,Ji P,Zhao XS,et al. Recombinant human TNK tissue-type plasminogen activator(rhTNK-tPA) versus alteplase(rt-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction(China TNK STEMI):protocol for a randomised,controlled,non-inferiority trial[J]. BMJ Open,2017,7(9):e016838.
[25] Gibson CM,Kumar V,Gopalakrishnan L,et al. Feasibility and safety of low-dose intra-coronary tenecteplase during primary percutaneous coronary intervention for ST-elevation myocardial infarction(ICE T-TIMI 49)[J]. Am J Cardiol,2020,125(4):485-490.
[26] 国家卫生计生委合理用药专家委员会,中国药师协会. 急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版) ,2019,11(1):40-65.
[27] Wang K,Zhang J,Zhang N,et al. Combined primary PCI with multiple thrombus burden reduction therapy improved cardiac function in patients with acute anterior myocardial infarction[J]. Int Heart J,2019,60(1):27-36.
[28] Abbas AE,Brewington SD,Dixon SR,et al. Intracoronary fibrin-specific thrombolytic infusion facilitates percutaneous recanalization of chronic total occlusion[J]. J Am Coll Cardiol,2005,46(5):793-798.
[29] Kelly RV,Crouch E,Krumnacher H,et al. Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention:initial experience with intracoronary tenecteplase[J]. Catheter Cardiovasc Interv,2005,66(3):327-332.
[30] So DY,Ha AC,Davies RF,et al. ST segment resolution in patients with tenecteplase-facilitated percutaneous coronary intervention versus tenecteplase alone:insights from the Combined Angioplasty and Pharmacological Intervention versus Thrombolysis ALone in Acute Myocardial Infarction(CAPITAL AMI) trial[J]. Can J Cardiol,2010,26(1):e7-e12.
[31] Gallagher S,Jain AK,Archbold RA. Intracoronary thrombolytic therapy:a treatment option for failed mechanical thrombectomy[J]. Catheter Cardiovasc Interv,2012,80(5):835-837.
[32] Boscarelli D,Vaquerizo B,Miranda-Guardiola F,et al. Intracoronary thrombolysis in patients with ST-segment elevation myocardial infarction presenting with massive intraluminal thrombus and failed aspiration[J]. Eur Heart J Acute Cardiovasc Care,2014,3(3):229-236.
[33] Jayagopal PB,Sarjun Basha KM. Intracoronary tenecteplase in STEMI with massive thrombus[J]. Indian Heart J,2018,70(3):446-449.
相似文献/References:
[1]谷阳 史亚非 张刚 张东营 张清.急性ST段抬高型心肌梗死患者血浆中性粒细胞明胶酶相关脂质运载蛋白水平与梗死后心室重构的相关性研究[J].心血管病学进展,2019,(5):836.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.042]
GU Yang,SHI Yafei,ZHANG Gang,et al.Neutrophil Gelatinase-associated Lipocalin is Associated with Cardiac Remodeling in Patients with ST-segment Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(9):836.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.042]
[2]郝明辉 郭明 唐宇 杨婧 柳子静 闫蕊 李萍 郭金成.急性ST段抬高型心肌梗死患者PCI后血清EREG水平及其与预后的关系[J].心血管病学进展,2020,(1):102.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.027]
HAO Minghui,GUO Ming,TANG Yu,et al.Serum EREG Level after PCI and Its Relationship with Prognosis in Patients with Acute ST-segment Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(9):102.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.027]
[3]赵鸿泽 刘剑雄.急性ST段抬高型心肌梗死介入手术时间窗与心室重塑的相关性研究[J].心血管病学进展,2020,(2):208.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.028]
ZHAO Hongze,LIU Jianxiong.Correlation between the Onset Time and Ventricular Remodeling in Scute ST-segment Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(9):208.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.028]
[4]邓媛 李伟 熊信林 段宗刚.急性ST段抬高型心肌梗死救治时间节点对预后影响的研究进展[J].心血管病学进展,2021,(11):1024.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
DENG Yuan,LI Wei,XIONG Xinlin,et al.Effect of Treatment Time Node on Prognosis of STEMI[J].Advances in Cardiovascular Diseases,2021,(9):1024.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[5]刘丽芳 彭瑜 张钲.急性ST段抬高型心肌梗死患者再灌注后心肌内出血的研究进展[J].心血管病学进展,2022,(5):444.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.015]
LIU Lifang,PENG Yu,ZHANG Zheng.Intracardial Hemorrhage After Reperfusion in Patients with Acute ST-Segment Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2022,(9):444.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.015]
[6]张兆元 马茜钰 张丹 彭石 张锦.C反应蛋白与高密度脂蛋白胆固醇比值、N末端脑钠肽前体与射血分数比值对STEMI患者PCI术后院内MACE的预测价值研究[J].心血管病学进展,2023,(2):186.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.020]
ZHANG ZhaoyuanMA QianyuZHANG DanPENG ShiZHANG Jin.The Predictive Value of C-reactive Protein to High Density Lipoprotein Cholesterol Ratio and NT-proBNP to Ejection Fraction Ratio for Hospital MACE in Patients with STEMI After PCI[J].Advances in Cardiovascular Diseases,2023,(9):186.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.020]
[7]苏利芳 汪雁博 刘畅畅 姜云发.急性ST段抬高型心肌梗死后支架置入时机的研究进展[J].心血管病学进展,2024,(5):429.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.011]
SU Lifang,WANG Yanbo,LIU Changchang,et al.The Timing of Stent Implantation for Acute ST S egment Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2024,(9):429.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.011]